With the increasing use of clinical genomic testing across broad medical disciplines, the need for data sharing and curation efforts to improve variant interpretation is paramount. The National 
INTRODUCTION
Broad genomic diagnostic technologies have been incorporated into routine clinical testing in many areas of medicine. Chromosomal microarray (CMA) is a first-tier test for patients with autism spectrum disorder, intellectual disability/developmental delay, and/or multiple congenital anomalies and for the prenatal evaluation of a fetus with structural anomalies (Manning & Hudgins, 2010; Muhle et al., 2017; Wapner et al., 2012) . Gene panels have often been used in the evaluation of genetically heterogenous disorders, such as hearing loss, neurological disorders, cardiovascular disorders, and hereditary cancer syndromes, whereas whole exome sequencing (WES) is increasingly employed for pediatric and adult patients when there is a broad differential diagnosis or for those with non-specific features (ACMG Board of Directors, 2012). These testing options have provided a diagnostic boon due to the breadth of genomic regions and genes interrogated. However, they have also resulted in a large number of rare variants of uncertain significance (VUS), requiring extremely large case and control datasets to help inform interpretation (Coe et al., 2014; Firth et al., 2009; Lek et al., 2016) . Data sharing across laboratories has emerged as a critical strategy to move variant interpretation efforts forward.
To facilitate this large-scale data sharing, the National Center for Biotechnology Information (NCBI) created the ClinVar database, which serves as a repository for clinical assertions about genomic variants, their associations with disease, and any supporting evidence provided with the submission (Azzariti et al., 2018; Landrum et al., 2014; Landrum et al., 2016) . The majority of ClinVar submissions come from clinical laboratories and are submitted as aggregate assertions, which therefore lack detailed case-level clinical descriptions and relevant family history information. While laboratories recognize the importance of clinical providers relaying details about a patient's clinical presentation, family history, and pertinent negative testing at the time of testing, this information is also important for variant curation efforts and other clinical providers who search for variants in ClinVar (Bush et al., 2017; Richards et al., 2015; Riggs, Jackson, Miller, & Van Vooren, 2012; Wain et al., 2012) .
The clinical provider's role in variant interpretation is increasingly being recognized (Baldridge et al., 2017; Bland et al., 2018; Wain, 2018; Zirkelbach et al., 2017) . The clinical provider is best suited to determine the most salient aspects of a patient's clinical history and is in the position to complete necessary post-test evaluations that can be key to informing a variant's interpretation, such as imaging, familial testing, or specialist referrals. Additionally, the clinical provider must make diagnoses and clinical recommendations based on the laboratory finding in the context of clinical correlation and judgment, a responsibility which relies on the clinical provider's unique expertise and assessment of the variant (Baldridge et al., 2017; Bland et al., 2018; Zirkelbach et al., 2017) . Clinical specialists who have accumulated this expertise have a perspective that is valuable in variant interpretation and curation efforts. Working in partnership with NCBI, the NIH-funded Clinical Genome Resource (ClinGen) is an international, collaborative effort to improve genomic medicine through multiple initiatives, including gene and variant curation, which incorporate the expertise of laboratory and clinical providers with particular disease expertise (Rehm et al., 2015) . Such submissions can help facilitate future research and variant identification via bioinformatics pipelines, which utilize ClinVar data annotations (Eilbeck, Quinlan, & Yandell, 2017; Harrison et al., 2016) .
We report the first large submission of clinically reported genomic variants to ClinVar by Geisinger's Autism & Developmental Medicine Institute (ADMI), a pediatric multidisciplinary neurodevelopmental clinical team. These variants, identified through routine clinical genomic testing for patients with autism spectrum disorder, intellectual disability/developmental delay, and/or multiple congenital anomalies, are submitted along with the clinical team interpretations of the variants and additional phenotypic or other clinical testing details that enhance the utility of the data in ClinVar.
METHODS
This ClinVar data submission proposal was reviewed by the Geisinger Institutional Review Board (IRB) and was determined to not meet the definition of research. Explicit consent was not required and no identifying information was included in the submission. Patients at ADMI are offered participation in our IRB-approved Making Advances Possible (MAP) protocol, which allows the use of clinically obtained data, including genomic test results, to be used for research purposes.
Approximately 95% of patients and their families who are invited to participate gave consent to the project. Data for this ClinVar submission were drawn from MAP-consented individuals.
A cascade genomic testing approach, including FMR1 analysis, CMA, and WES, is the standard of care for patients who are evaluated at ADMI and diagnosed with autism spectrum disorder, global developmental delay, intellectual disability, and/or multiple congenital anomalies. All testing is ordered as part of routine clinical care and insurance coverage is determined prior to ordering each step of the cascade. ADMI has generally been successful in obtaining insurance coverage for these clinical tests through commercial plans; many of our patients are insured by a Geisinger Health Plan policy, including a Geisinger Medicaid plan, which provides coverage for WES for patients with the above indications. Single gene or gene panel testing is considered on a case-by-case basis, typically for patients with very specific phenotypic presentations or insurance coverage gaps.
The ADMI medical genetics team routinely assesses the clinical significance of variants obtained through clinical testing by critically reviewing available gene and variant-specific evidence and seeking additional evidence that might not be specified in the laboratory report. Evidence is evaluated using published guidelines for copy number and sequence variants from the American College of Medical Genetics and Genomics (ACMG) and the ACMG/Association for Molecular Pathology (AMP), respectively (Kearney, Thorland, Brown, Quintero-Rivera, & South, 2011; Richards et al., 2015) . These assess- Genomic test results from MAP-consented probands were queried and variants were selected for ClinVar submission. Copy number variants (CNVs) representing well-documented, recurrent chromosomal deletion or duplication syndromes were excluded. Five CNVs could not be submitted due to incomplete data or because the CNV was reported on a genome build not supported by ClinVar (hg17). Non-recurrent CNVs were submitted to ClinVar, but were not considered completely novel submissions in our data analysis if overlapping CNVs with very similar genomic breakpoints had been previously submitted. Additionally, two sequence variants were excluded because they are well documented in ClinVar, and our data provided no additional value.
Phenotype data were provided using terms from the Human Phenotype Ontology (Köhler et al., 2017; Robinson & Mundlos, 2010) , as well as in a narrative comment field description. Five initial variants were submitted as a proof of concept in April 2017 (SUB2634283) using the "SubmissionTemplateLite" file via the ClinVar Submission Portal, with "clinical testing" as the collection method. An additional 143 sequence variants and 155 CNVs were submitted to ClinVar using the standard "SubmissionTemplate" Excel submission file and the newly developed collection method of "provider interpretation" (SUB3843551, sequence variants; SUB3918644, CNVs on GRCh37; SUB3918759, CNVs on GRCh36) (Landrum et al., 2018) . The "provider interpretation" collection method includes the testing laboratory that identified the variant, the laboratory's interpretation, and the report date. These data can help ClinVar users understand that both the clinician and reporting laboratory may submit the variant and additional information about the variant to the database (Landrum et al., 2018) . In a small number of cases, the ADMI interpretation differed from the laboratory classification. In an attempt to resolve these discrepancies, the ADMI genetic counselor discussed any differences and the supporting evidence with the testing laboratory. At times, discussing these differences resulted in a changed interpretation by the clinical provider or the laboratory, but in three instances (2%) these differences were not fully resolved (Table 1 ). In the case of the family with a PTEN variant described in case example 2 below, the ADMI team's clinical expertise informed a higher confidence in clinical correlation, which allowed us to apply an additional ACMG/AMP criterion (PP1).
RESULTS

Out
Our clinical judgment resulted in a more conservative interpretation of the published literature in another case, and the third unresolved discrepancy was attributable to laboratory inclusion of unpublished internal data, to which we did not have access. We also observed 32 discrepancies in CNV classification due to outdated interpretation category terms, such as the use of "abnormal" or "positive" in older reports. In 31.3% of these, the ADMI interpretation was VUS, illustrating the importance of variant reassessment by clinical providers to ensure that up-to-date interpretations can be incorporated into clinical decision making.
The following are selected case examples that illustrate how clinical provider ClinVar submissions can be valuable for the clinical community, beyond simply submitting novel variants and regardless of the concordance between laboratory and clinical provider interpretation.
Case 1: Provision of post-test clinical outcomes and additional relevant literature citations
WES (trio analysis) was performed for a 5-year-old girl with global developmental delay, epilepsy, esotropia, a wide-based gait, and hypotonia. Her father had a history of learning disability and her mother had mild intellectual disability, epilepsy, and paroxysmal kinesigenic dyskinesia. A maternally inherited missense variant in SLC2A1 was identified (c.1199G>A, p.Arg400His). This variant has been previously reported in individuals with glucose transporter type 1 deficiency syndrome (Glut1DS, OMIM 606777) and was classified as pathogenic by the laboratory (Ito et al., 2015; Mullen et al., 2011; Vieker, Schmitt, Langler, Schmidt, & Klepper, 2012) . This result provided a diagnosis for our proband and her mother. Both were referred for a nutrition consultation to discuss implementation of ketogenic diet. The proband, who is cared for by her paternal grandmother, has successfully adapted to 
Case 3: Post-test follow-up clinical evaluations that inform variant interpretation and define genomic regions of clinical impact
CMA was performed for a 5-year-old girl with autism spectrum disorder, global developmental delay, attention deficit hyperactivity disorder (ADHD), wide-spaced teeth, and a history of feeding and sleep problems. A 142 kilobase, paternally inherited deletion was identified at 11p13 (chr11:31,312,348-31,454,239 × 1, GRCh37). Her father has a history of ADHD and bipolar disorder, though no history of learning difficulties. Similar deletions have been identified rarely in both cases and controls (Coe et al., 2014) . This deletion is located telomeric to the PAX6 gene and the ELP4 gene, which is thought to harbor a PAX6 regulatory region (Balay et al., 2015) . Loss-of-function or disruption of PAX6 is known to cause aniridia and other ophthalmologic abnormalities (Hingorani et al., 2003) . The deletion was reported as a VUS due to lack of knowledge of this genomic region in general.
Our patient was referred for an ophthalmologic evaluation, which was normal, and her father has normal vision. This post-test clinical evaluation supports the genomic boundaries of the proposed PAX6 regulatory region previously published (Balay et al., 2015) , indicating that the deletion is outside of this regulatory region. However, the association of a deletion of this region with the patient's neurodevelopmental diagnoses and her father's psychiatric history remains uncertain.
DISCUSSION
As large-scale genomic testing has become more broadly incorporated into medical care, the number of novel, rare genomic variants identified has proven to be a major hurdle for the field of clinical variant interpretation. To address this challenge, genomic data sharing through ClinVar and other databases has emerged as a highly successful means of pooling data across clinical laboratories, researchers, the literature, and other stakeholders (Azzariti et al., 2018; Landrum et al., 2014; Landrum et al., 2016; Landrum et al., 2018) . Data sharing has facilitated the resolution of interpretation discrepancies and is useful for bioinformatic approaches to clinical and research genomic testing (Eilbeck et al., 2017; Harrison et al., 2016; Harrison et al., 2017; Yang et al., 2017) . Additionally, the Clinical Genome Resource (ClinGen) has been instrumental in organizing and leading the collaborative curation of genes and variants to increase expert consensus of their medical relevance, a task in which clinical providers are engaged. Despite these strides, the role of the clinical provider as an active contributor to genomic variant data sharing efforts has not yet been fully realized.
Variant interpretation practices, such as searching variant databases and evaluating evidence according to published guidelines, are increasingly being acknowledged as relevant to clinical genetics providers' practice (Baldridge et al., 2017; Bland et al., 2018; Wain, 2018; Zirkelbach et al., 2017) , and educational sessions on this topic have been well attended at national genetics conferences (ACMG, 2017 (ACMG, , 2018 NSGC, 2017) 
Contribute variants that have not been shared previously
The majority of genomic variants (63.4%) identified in our patients through routine clinical testing had not been submitted to ClinVar previously, despite prioritizing the use of clinical laboratories that share data regularly. This observation demonstrates the invaluable contribution of clinical provider engagement in genomic variant data sharing, rather than relying only on clinical laboratories to build this shared resource. Large commercial laboratories typically have several distinct areas of disease or technical expertise and data sharing practices may not be consistent across all areas. Also, laboratories may choose to submit some types of variants and retain others, such as variants in genes of uncertain significance, within internal data only. These data sharing practices may be due to a perception that VUSs in ClinVar are less useful, time and workforce limitations, or laboratory decision to first gather internal data to facilitate publications and enable collaborations with ordering providers. While such partnerships and publications are valuable, these data sharing decisions can also delay the dissemination of information that may prove useful for a clinical provider at point-ofcare. This practice also reduces the chance that genomic variants that are ultimately determined to be likely benign or benign are shared publicly because these variants are less likely to be published.
Provide detailed clinical descriptions
The importance of submitting patient phenotype and family history information to a testing laboratory for variant interpretation purposes has been acknowledged previously (Bush et al., 2017; Richards et al., 2015; Riggs et al., 2012; Wain et al., 2012) 
Facilitate inclusion of updated interpretations and curation efforts
The clinical interpretation of a genomic variant is derived at a given point in time, using available evidence and resources and interpreted Providing this information enhances the utility of ClinVar and allows one clinical provider's work to potentially help other providers who are caring for patients with the same or a similar genomic variant.
At times, the clinical provider may interpret the clinical significance of a variant differently than the laboratory, and these differences may not always be resolved through direct discussion. We observed this for three sequence variants (2%) from this data submission (Table 1) .
These instances reflect the need for the clinical provider to think about a variant's impact independently. In our experience, these interpretation differences were associated with three situations: (1) 
Be informed of variants with updated interpretations
ClinVar submissions also provide a potential mechanism for the clinical provider to receive notifications about variant interpretation discrepancies, which may occur over time as variants are reclassified by other ClinVar submitters (Harrison et al., 2017; Landrum et al., 2016) . Staying abreast of variant reclassifications has been acknowledged as a logistical challenge for clinical providers and has resulted in debate regarding where the responsibility for this lies: the laboratory, the clinical provider, the patient, and so on (Bowdin et al., 2016; Richards et al., 2015 
Foster ongoing development and collaboration
Understanding how clinical providers approach variant interpretation can help foster professional development and education in this area.
Familiarity with the ClinVar submission process is useful in helping clinical providers appreciate the benefits and limitations of the ClinVar database, and this understanding can help fuel additional input from these stakeholders regarding the use and design of ClinVar moving forward. For example, through our participation in ClinGen we were able to express our interest in clinical provider ClinVar submissions and contribute to the creation of the "provider interpretation" submission type (Landrum et al., 2018) . While ADMI has an internal database that captured much of the data needed for this ClinVar submission, this initial large submission still involved manual curation requiring significant time over and above routine clinical practice. However, this experience has informed database improvements and changes to genetic counselors' clinical practices that are expected to increase efficiency for subsequent submissions, case management, and future publications.
Incorporating ClinVar submissions as a priority for clinical providers could spark improved genomic data organization and database infrastructure within the provider's institution, promoting the use of clinical data for research and healthcare improvements. As a learning healthcare system, Geisinger supports such clinical provider engagement and leverages such data to inform insurance policy updates and workflow improvements. Contributing to ClinVar could be a useful goal for a clinical team as they implement elements of variant interpretation into routine practice. 
CONCLUSION
The Geisinger ADMI submission of sequence variants and CNVs to in variant interpretation and ClinVar submission will continue to be developed to facilitate this important mechanism for data sharing.
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